Forty-one patients with active RA despite disease-modifying antirheumatic drug therapy were randomised 2:1 to CZP ( CZP loading dose 400mg every 2weeksat weeks 0-4 ; CZP 200mg every 2weeksat weeks 6-16 ) or placeboCZP ( placebo at weeks 0-2 ; CZP loading dose at weeks 2-6 ; CZP 200mg every 2weeks at weeks 8-16 ) .